HOME >> BIOLOGY >> NEWS
American Institute of Chemists names Ralph Hirschmann AIC Gold Medalist

PHILADELPHIA 11 April 2003 The American Institute of Chemists (AIC) and the Chemical Heritage Foundation (CHF) will present the 2003 AIC Gold Medal to Ralph F. Hirschmann. The award ceremony will be part of Heritage Day festivities at CHF in Philadelphia, Pennsylvania, on Thursday, 12 June 2003.

It is fitting that the first AIC Gold Medal awarded jointly by CHF and the AIC be presented to a pharmaceutical researcher with the talent, skills, and insight of Ralph Hirschmann, said Arnold Thackray, president of CHF. At Merck, he was head of the effort that developed effective drugs to treat hypertension, congestive heart failure, severe infection, river blindness in developing countries, and many other illnesses. His remarkable accomplishments as a researcher include the synthesis of the enzyme ribonuclease in solution, the first example of protein synthesis.

The presentation of the AIC Gold Medal will be part of a day devoted to celebrating the achievement and promise of the chemical and molecular sciences. Heritage Day begins with the awarding of the Othmer Gold Medal to John D. Baldeschwieler and George S. Hammond. In the late afternoon, Hirschmann will receive the AIC Gold Medal. Following a reception, the Winthrop-Sears Medal of The Chemists Club will be presented at a dinner at nearby Carpenters Hall.

Ralph F. Hirschmann
Ralph F. Hirschmann is Makineni Professor of Bioorganic Chemistry at the University of Pennsylvania. He joined the Penn faculty in 1987 after retiring as Mercks senior vice president of basic research. He was affiliated with Merck for 37 years, during which time he fostered interdisciplinary research as well as collaborations between academia and industry, practices he has continued at Penn.

Several widely used medications stem from Hirschmanns tenure at Merck, including the parasite-fighting Ivomec. And, in a major theoretical contribution to organic chemistry, he was the first to discover that chem
'"/>

Contact: Neil Gussman
neilg@chemheritage.org
717-314-2494
Chemical Heritage Foundation
16-Apr-2003


Page: 1 2

Related biology news :

1. Highlights of the October 2004 Journal of the American Dietetic Association
2. The American Phytopathological Society announces 2004 awards
3. Tips from the Journals of the American Society for Microbiology
4. Highlights of American Chemical Society national meeting in Philadelphia, Aug. 22-26
5. NIH roadmap for biomedical research focus of chemists at American Chemical Society meeting
6. Tips from the journals of the American Society for Microbiology
7. Genetic mutation linked to more aggressive breast cancer found more often in African-Americans
8. More aggressive breast cancer tumors found in African American women
9. American Society of Mammalogists honors CI president Russell Mittermeier with Aldo Leopold award
10. Tips from the Journals of the American Society for Microbiology
11. Most Americans not sure about the sources of high cholesterol

Post Your Comments:
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Md. , March 30, 2015  Spherix ... company committed to the fostering and monetization of ... v. VTech,  Case No. 3:13-cv-03494-M and  Spherix v. ... United States District Court for the Northern District ... update regarding Spherix v. Verizon, Case ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: